A pilot phase II study of alternate day ganciclovir and foscarnet in preventing cytomegalovirus (CMV) infections in at-risk pediatric and adolescent allogeneic stem cell transplant recipients

Pediatric Blood and Cancer

Volumn 49, Issue 3, 2007, Pages 306-312

  Shereck, Evan B ^a   Cooney, Erin ^a   Van De Ven, Carmella ^a   Della Lotta, Phyllis ^a   Cairo, Mitchell S ^a,b  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b Department of Pediatrics Medicine and Pathology

Author keywords

Cytomegalovirus; Foscarnet; Ganciclovir

Indexed keywords

ALEMTUZUMAB; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPHOTERICIN B LIPID COMPLEX; BUSULFAN; CD34 ANTIGEN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; ETOPOFOS; ETOPOSIDE; FLUDARABINE; FOSCARNET; GANCICLOVIR; GEMCITABINE; GEMTUZUMAB OZOGAMICIN; MELPHALAN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; TACROLIMUS; THYMOCYTE ANTIBODY; VANCOMYCIN;

ADOLESCENT; ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; BLOOD TOXICITY; CHILD; CHILDHOOD CANCER; CLINICAL TRIAL; CONTINUOUS INFUSION; CREATININE BLOOD LEVEL; CYTOMEGALOVIRUS INFECTION; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELECTROLYTE DISTURBANCE; FEMALE; GRAFT VERSUS HOST REACTION; HEMATOLOGIC DISEASE; HUMAN; HYPOCALCEMIA; HYPOMAGNESEMIA; HYPOPHOSPHATEMIA; IMMUNOSUPPRESSIVE TREATMENT; INFANT; INFECTION RISK; KIDNEY DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; OVERALL SURVIVAL; PANCREATITIS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANTIVIRAL AGENTS; CHILD; CHILD, PRESCHOOL; CYTOMEGALOVIRUS INFECTIONS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; DRUG TOXICITY; FEMALE; FOSCARNET; GANCICLOVIR; GRAFT VS HOST DISEASE; HUMANS; INFANT; MALE; PILOT PROJECTS; STEM CELL TRANSPLANTATION; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 34547775136     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.21043     Document Type: Article

References (23)

1. Meyers JD, Flournoy N, Thomas ED. Risk factors for cytomegalovirus infection after human marrow transplantation. J Infect Dis 1986;153:478-488.
2. Miller WJ, McCullough J, Balfour HH, Jr., et al. Prevention of cytomegalovirus infection following bone marrow transplantation: A randomized trial of blood product screening. Bone Marrow Transplant 1991;7:227-234.
3. Walter EA, Greenberg PD, Gilbert MJ, et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med 1995;333:1038-1044.
4. Reed EC, Bowden RA, Dandliker PS, et al. Treatment of cytomegalovirus pneumonia with ganciclovir and intravenous cytomegalovirus immunoglobulin in patients with bone marrow transplants. Ann Intern Med 1988;109:783-788.
5. Emanuel D, Cunningham I, Jules-Ely see K, et al. Cytomegalovirus pneumonia after bone marrow transplantation successfully treated with the combination of ganciclovir and high-dose intravenous immune globulin. Ann Intern Med 1988;109:777-782.
6. Bowden RA, Sayers M, Flournoy N, et al. Cytomegalovirus immune globulin and seronegative blood products to prevent primary cytomegalovirus infection after marrow transplantation. N Engl J Med 1986;314:1006-1010.
7. Crumpacker CS. Ganciclovir. N Engl J Med 1996;335:721-729.
8. Goodrich JM, Mori M, Gleaves CA, et al. Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation. N Engl J Med 1991;325:1601-1607.
9. Winston DJ, Ho WG, Bartoni K, et al. Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients. Results of a placebo- controlled, double-blind trial. Ann Intern Med 1993;118:179-184.
10. Boeckh M, Leisenring W, Riddell SR, et al. Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: Importance of viral load and T- cell immunity. Blood 2003;101:407-414.
11. Oberg B. Antiviral effects of phosphonoformate (PFA, foscarnet sodium). Pharmacol Ther 1989;40:213-285.
12. Deray G, Martinez F, Katlama C, et al. Foscarnet nephrotoxicity: Mechanism, incidence and prevention. Am J Nephrol 1989;9:316-321.
13. Peters M, Schurmann D, Bergmann F, et al. Safety of alternating ganciclovir and foscarnet maintenance therapy in human immunodeficiency virus (HIV)-related cytomegalovirus infections. An open-labeled pilot study. Scand J Infect Dis 1994;26:49-54.
14. Luhm RA, Bellissimo DB, Uzgiris AJ, et al. Quantitative evaluation of post-bone marrow transplant engraftment status using fluorescent-labeled variable number of tandem repeats. Mol Diagn 2000;5:129-138.
15. Osunkwo I, Bessmertny O, Harrison L, et al. A pilot study of tacrolimus and mycophenolate mofetil graft-versus-host disease prophylaxis in childhood and adolescent allogeneic stem cell transplant recipients. Biol Blood Marrow Transplant 2004;10:246-258.
16. Przepiorka D, Weisdorf D, Martin P, et al. 1994. Consensus conference on acute GVHD grading. Bone Marrow Transplant 1995;15:825-828.
17. Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 1974;18:295-304.
18. Ljungman P, Griffiths P, Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis 2002;34:1094-1097.
19. Wingard JR, Boeckh M, Nichols G. Current treatment and prevention options for CMV. Blood Marrow Transplant 2003;13:3-6.
20. Nachbaur D, Larcher C, Kircher B, et al. Risk for cytomegalovirus infection following reduced intensity allogeneic stem cell transplantation. Ann Hematol 2003;82:621-627.
21. Junghanss C, Boeckh M, Carter RA, et al. Incidence and outcome of cytomegalovirus infections following nonmyeloablative compared with myeloablative allogeneic stem cell transplantation, a matched control study. Blood 2002;99:1978-1985.
22. Hakki M, Riddell SR, Storek J, et al. Immune reconstitution to cytomegalovirus after allogeneic hematopoietic stem cell transplantation: Impact of host factors, drug therapy, and subclinical reactivation. Blood 2003;102:3060-3067.
23. Centers for Disease Control and Prevention DHHS. Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients; 2000; October 20. Report nr 49(RR10). 1-128 p.